{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:04:26Z","timestamp":1792760666941,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtha.2025.11.022","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:22:54Z","timestamp":1766420574000},"page":"1388-1396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Apixaban vs vitamin K antagonists in relation to postthrombotic syndrome: data from a prospective cohort study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6829-1767","authenticated-orcid":false,"given":"Annisa","family":"Aarts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Brandts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Pavlicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo ten","family":"Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arina J.","family":"ten Cate-Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.11.022_bib1","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.11.022_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0268-960X(02)00008-5","article-title":"The post-thrombotic syndrome: current knowledge, controversies, and directions for future research","volume":"16","author":"Kahn","year":"2002","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2025.11.022_bib3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2009.07601.x","article-title":"Post-thrombotic syndrome: prevalence, prognostication and need for progress","volume":"145","author":"Prandoni","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.11.022_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2019.03.003","article-title":"Post-thrombotic syndrome: short and long-term incidence and risk factors","volume":"177","author":"Ende-Verhaar","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.022_bib5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1538-7836.2009.03294.x","article-title":"Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization","volume":"7","author":"Kahn","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/rth2.12085","article-title":"Prevention and treatment of the post-thrombotic syndrome","volume":"2","author":"Ten Cate-Hoek","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.7326\/0003-4819-126-6-199703150-00006","article-title":"Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden","volume":"126","author":"Bergqvist","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.11.022_bib8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archinte.162.10.1144","article-title":"Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis","volume":"162","author":"Kahn","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2025.11.022_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11239-009-0309-3","article-title":"Incidence and cost burden of post-thrombotic syndrome","volume":"28","author":"Ashrani","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.11.022_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1538-7836.2005.01333.x","article-title":"Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome","volume":"3","author":"van Dongen","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib11","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1538-7836.2012.04872.x","article-title":"Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study","volume":"10","author":"Chitsike","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.thromres.2014.06.010","article-title":"Biomarkers for post thrombotic syndrome: a case-control study","volume":"134","author":"Bouman","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.022_bib13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/rth2.12443","article-title":"Effect of anticoagulants on fibrin clot structure: a comparison between vitamin K antagonists and factor Xa inhibitors","volume":"4","author":"Gauer","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/0003319719840861","article-title":"Nonhemostatic activities of factor Xa: are there pleiotropic effects of anti-FXa direct oral anticoagulants?","volume":"70","author":"Papadaki","year":"2019","journal-title":"Angiology"},{"key":"10.1016\/j.jtha.2025.11.022_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10557-020-07010-z","article-title":"Apixaban downregulates endothelial inflammatory and prothrombotic phenotype in an in vitro model of endothelial dysfunction in uremia","volume":"35","author":"Torramade-Moix","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jtha.2025.11.022_bib16","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.022_bib17","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.3390\/jcm12237450","article-title":"A systematic review and Bayesian network meta-analysis on the effect of different anticoagulants on the prophylaxis of post-thrombotic syndrome after deep venous thrombosis","volume":"12","author":"Shao","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.11.022_bib18","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.11.022_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1160\/TH16-01-0041","article-title":"Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis","volume":"116","author":"Cheung","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2017.05.029","article-title":"Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome","volume":"157","author":"Jeraj","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.022_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1076029618758955","article-title":"Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism","volume":"24","author":"Coleman","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.thromres.2018.01.013","article-title":"Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome","volume":"163","author":"Utne","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.022_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2019.106608","article-title":"Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban","volume":"124","author":"Ferreira","year":"2020","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jtha.2025.11.022_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.thromres.2020.09.014","article-title":"Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: a systematic review and meta-analysis","volume":"196","author":"Li","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.11.022_bib25","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jvsv.2021.04.016","article-title":"Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: a systematic review and meta-analysis","volume":"9","author":"Karathanos","year":"2021","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.jtha.2025.11.022_bib26","doi-asserted-by":"crossref","first-page":"e12748","DOI":"10.1002\/rth2.12748","article-title":"Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin","volume":"6","author":"Bistervels","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib27","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/jth.15449","article-title":"Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: a long-term cross-sectional follow-up of RE-COVER study patients","volume":"19","author":"Wik","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11739-019-02215-z","article-title":"The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants","volume":"15","author":"Prandoni","year":"2020","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jtha.2025.11.022_bib29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/00033197211070889","article-title":"Risk factors for post-thrombotic syndrome in patients with a first proximal deep venous thrombosis treated with direct oral anticoagulants","volume":"73","author":"Spiezia","year":"2022","journal-title":"Angiology"},{"key":"10.1016\/j.jtha.2025.11.022_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/rth2.12079","article-title":"Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction","volume":"2","author":"Nagler","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib31","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/S2352-3026(17)30227-2","article-title":"Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial","volume":"5","author":"Ten Cate-Hoek","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.11.022_bib32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-137-12-200212170-00008","article-title":"Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism","volume":"137","author":"Prandoni","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.11.022_bib33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"71","author":"Hicks","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.11.022_bib34","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.11.022_bib35","doi-asserted-by":"crossref","first-page":"A116","DOI":"10.1016\/j.jvs.2007.02.034","article-title":"Molecular characterization of post-thrombotic syndrome","volume":"45","author":"Phillips","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jtha.2025.11.022_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227150","article-title":"Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome","volume":"15","author":"Bittar","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.11.022_bib37","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.3390\/ijms25168727","article-title":"Beyond anticoagulation: a comprehensive review of non-vitamin K oral anticoagulants (NOACs) in inflammation and protease-activated receptor signaling","volume":"25","author":"Jannati","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2025.11.022_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/678159","article-title":"Obesity and inflammation: epidemiology, risk factors, and markers of inflammation","volume":"2013","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2013","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.jtha.2025.11.022_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235639","article-title":"Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: a cohort study","volume":"15","author":"van Miert","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.11.022_bib41","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2352-3026(19)30209-1","article-title":"Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial","volume":"7","author":"Notten","year":"2020","journal-title":"Lancet Haematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500902X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500902X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:17:43Z","timestamp":1781939863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362500902X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S153878362500902X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.022","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apixaban vs vitamin K antagonists in relation to postthrombotic syndrome: data from a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}